Zydus receives final approval from USFDA and 180 days shared exclusivity for Brivaracetam Tablets

Brivaracetam is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.

Lupin receives approval from USFDA for Darunavir Tablets

The product will be manufactured at Lupin's facility in Nagpur, India.

Zydus receives approval from USFDA for Mirabegron Extended-Release Tablets

Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urinary incontinence, urgency, and frequency

Lupin receives US FDA approval for Mirabegron Extended-Release tablets

Mirabegron Extended-Release Tablets, 25 mg and 50 mg, had estimated annual sales of US $2.4 billion in US

Shilpa Medicare receives tentative approval for Tenofovir Alafenamide Tablets

The ANDA was filed as 'First to File' submission on NCE-1 date.

Dolomite Bio launches an affordable microfluidic system for custom protocol development

Dolomite Bio scientist demonstrating pipetting into the Nadia Go

Affordable Sitagliptin combinations for diabetics to be sold at Janaushadhi Kendras

Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Ashland to expand bioresorbable polymers capacity in Ireland

The capital expansion program commenced in June 2022 and is expected to complete in 2024

USFDA inspection at Alembic Pharmaceuticals Injectable Facility (F-3) at Karkhadi

Zydus receives final approval from USFDA for two tablets

The group now has 322 approvals and has so far filed over 428 ANDAs since the commencement of the filing process in FY 2003-04